Mass spectrometry for peptide identity: ESI mass spec vs LC-MS/MS sequence verification

Mass spectrometry is the analytical method that confirms peptide identity at the molecular level, HPLC tells you the molecule is pure, mass spec tells you what the molecule is. For pharmaceutical-grade peptide work, two mass-spec techniques cover different aspects of identity confirmation: ESI mass spec for molecular weight, and LC-MS/MS for sequence verification.

This article explains what each technique measures, when each is necessary, and how the released-batch COA should report both.

ESI mass spec: molecular weight confirmation

ESI (electrospray ionization) mass spec is the workhorse identity-confirmation method for peptide release testing. The technique works by spraying the sample in solution through a charged needle into a vacuum chamber, where the solvent evaporates and the peptide molecules acquire one or more proton charges. The resulting positively-charged ions are then analyzed in a mass analyzer (typically Orbitrap or quadrupole-time-of-flight in modern facilities) to determine the mass-to-charge ratio.

For a peptide, the ESI mass spec produces a characteristic charge-state envelope: a small peptide (say, 10 residues, ≈1000 Da) typically shows a single dominant +1 or +2 charge state; a larger peptide (say, 40 residues, ≈4000 Da) shows multiple charge states from +2 to +6, each corresponding to a different protonation state of the same molecule. The mass analyzer deconvolutes the charge-state envelope back to the neutral molecular weight.

The released-batch COA should report:

• Observed molecular weight, measured by ESI mass spec
• Theoretical molecular weight, computed from the peptide sequence and any modifications
• Mass accuracy, the difference between observed and theoretical, expressed as ppm (parts per million) for high-resolution Orbitrap measurements or as Da for unit-resolution measurements
• Charge-state envelope, at minimum, the charge states observed; ideally, the full deconvoluted spectrum

For high-resolution Orbitrap measurements, mass accuracy is typically better than 5 ppm, for a 4000 Da peptide, that's better than 0.02 Da. For unit-resolution quadrupole measurements, mass accuracy is typically within 0.5 Da. Either is sufficient to confirm the molecular weight matches the target.

What ESI mass spec doesn't tell you

A single mass-spec measurement confirms the molecular weight matches the target, but it doesn't necessarily confirm the sequence. Several distinct molecules can share the same mass:

Deletion sequences from SPPS, A single-residue deletion at a specific position produces a peptide with one amino acid missing. If two amino acids have the same mass (Leu and Ile are exact mass-equivalents; Asn and Asp differ by only 1 Da), a deletion at one residue and an insertion at another can produce a mass-equivalent variant.

Sequence-scrambling, In theory, a peptide could be synthesized with the residues in a different order. The mass would be identical to the correct sequence; the biology would be entirely different.

Stereochemistry, D-amino acid substitutions don't change the mass at all. A peptide synthesized with all-D amino acids has the same mass as the all-L version but profoundly different biological activity.

For short peptides (5-10 residues), the mass-alone identity confirmation is usually sufficient because the number of plausible alternative-sequence variants is small. For longer peptides (15+ residues), mass-alone confirmation leaves substantial identity ambiguity, and tandem mass spectrometry (LC-MS/MS) becomes the recommended second analytical step.

LC-MS/MS sequence verification

LC-MS/MS (also called tandem mass spectrometry) extends the mass-spec analysis to confirm the sequence at the residue level. The technique works in two stages:

1. **MS1 selection**, Select a specific charge state of the peptide ion (typically the +2 or +3 state for a medium-sized peptide) and isolate it from the rest of the sample.
2. **MS2 fragmentation**, Apply collision energy in a collision cell, fragmenting the peptide backbone at the peptide-bond positions to produce a series of fragment ions.

The fragmentation pattern is highly informative. For a peptide of length n, the backbone can fragment at any of the n-1 peptide bonds, producing two complementary ion series:

• b-ions, N-terminal fragments retaining the N-terminus. b1 is the first residue, b2 is the first two residues, etc.
• y-ions, C-terminal fragments retaining the C-terminus. y1 is the last residue, y2 is the last two residues, etc.

For a 10-residue peptide, the complete b/y-ion ladder produces 9 b-ions and 9 y-ions covering the full sequence. Each ion's mass corresponds to the cumulative mass of the residues it contains, so the differences between consecutive b-ions (or y-ions) reveal the individual residue masses in sequence. Comparing the observed b/y-ladder against the theoretical ladder for the target sequence confirms (or refutes) the sequence at the residue level.

The standard analytical-output for a sequence-verification report:

• Coverage, what fraction of the b/y-ions in the theoretical ladder were observed (typically ≥80% coverage is acceptable; 100% is ideal)
• Position confidence, for each residue position, how confidently the observed fragment ions confirm that residue (high confidence = b-ion and y-ion both observed at that position; lower confidence = only one of the two)
• Anomaly flags, any unexpected ions that don't fit the theoretical sequence

For peptides above 15 residues, sequence verification by LC-MS/MS is the analytical test that meaningfully distinguishes one supplier's identity confirmation from another's. Without it, mass-alone confirmation leaves space for deletion sequences, sequence-scrambling, and isomer impurities to pass undetected.

When each technique is appropriate

For short peptides (≤15 residues): ESI mass spec alone is generally sufficient for routine release testing, because mass-alone identity confirmation has limited ambiguity at this length.

For medium peptides (15-30 residues): ESI mass spec at every batch release + LC-MS/MS at first-time supplier qualification is the recommended pattern. The LC-MS/MS confirms the synthesis route is producing the correct sequence; subsequent batch releases can rely on the established route + mass-alone confirmation.

For long peptides (30+ residues, e.g., Tirzepatide at 39, Semaglutide at 31, Retatrutide at 39, TB-500 at 43): LC-MS/MS sequence verification on every release batch is the conservative practice. The synthesis is complex enough that batch-to-batch quality drift can produce different impurity profiles, and the analytical depth should match the molecular complexity.

For modified peptides (lipidated, PEGylated, copper-coordinated, D-amino-acid-containing): LC-MS/MS confirms both the sequence and the modification position, which mass-alone confirmation cannot distinguish. Modified peptides essentially always merit the deeper analytical scope.

How to read a sequence-verification report

A well-formatted LC-MS/MS sequence-verification report should include:

1. **The theoretical b/y-ion table**, listing each expected fragment mass for the target sequence
2. **The observed b/y-ion table**, listing each fragment mass observed in the MS2 spectrum
3. **The match table**, showing which theoretical ions were observed, and within what mass tolerance
4. **The annotated spectrum**, the raw MS2 spectrum with peaks labeled by which b- or y-ion they correspond to
5. **The sequence coverage statement**, what percentage of the sequence is confirmed by the observed ions
6. **Anomaly notes**, any unexpected ions that don't fit the theoretical pattern, with the analyst's interpretation

Vialdyne's LC-MS/MS reports include all six elements. For peptides above 15 residues, the report is part of the released-batch documentation by default. For shorter peptides, the LC-MS/MS test is available on request, discuss the analytical scope at quote stage.

For more on the broader analytical packet and what every COA field measures, see our COA buyer's field guide and the companion HPLC method development article.